Zantac Brand vs. Generic — All Manufacturers Are Liable

The Zantac Brand History — Multiple Owners, One Molecule

Branded Zantac has had multiple corporate owners since ranitidine was first developed. The drug was originally discovered and developed by Glaxo (later GlaxoSmithKline / GSK), which introduced Zantac to the U.S. market in 1983 and held the brand through its patent protection period. After patent expiration, Pfizer acquired the Zantac brand and related OTC consumer healthcare assets from GSK's consumer division. Sanofi S.A. subsequently acquired Pfizer's consumer healthcare unit, including Zantac, making Sanofi the most recent owner of the Zantac brand at the time of the FDA market withdrawal in April 2020. All three companies — GSK, Pfizer, and Sanofi — are named defendants in Zantac litigation, and claimants' exposure periods may cover one or more of their respective tenure periods as Zantac brand holders.

Generic Ranitidine Manufacturers — The Same Liability

Boehringer Ingelheim is the most significant generic ranitidine manufacturer in Zantac litigation. Boehringer Ingelheim manufactured and distributed generic ranitidine products under private label and retailer-brand agreements, making its products widely available across major retail chains as store-brand antacids. Other generic manufacturers also produced and distributed ranitidine, and their products are equally implicated because the NDMA issue arises from the ranitidine API (active pharmaceutical ingredient) itself, not from any specific excipient or manufacturing process used by a particular company. Store-brand ranitidine sold by CVS Health, Walgreens Boots Alliance, Walmart, Target, Rite Aid, Costco, and other retailers is also covered by litigation — the store brand designations merely identify the retailer; the underlying API came from generic manufacturers who are named defendants.

Why Multiple Defendants Benefit Claimants

The availability of multiple defendant companies with substantial financial resources and insurance coverage is a significant practical advantage for Zantac claimants. Unlike litigation against a single small manufacturer that might declare bankruptcy and limit recoveries, the Zantac defendants — Sanofi (a major global pharmaceutical company), GSK (one of the world's largest pharmaceutical companies), Pfizer (the world's largest pharmaceutical company by certain metrics), and Boehringer Ingelheim (a privately held multinational) — collectively represent some of the most financially solvent companies in the world. Even if one defendant prevails at trial or reaches an early global settlement, other defendants remain in the litigation. Claimants who used both branded Zantac and generic ranitidine over their use history may have claims against multiple defendants.

How to Identify Which Manufacturer Made Your Ranitidine

Many consumers who took ranitidine over years purchased both branded Zantac and generic or store-brand versions interchangeably — whichever was on sale or available at the time. Pharmacy records typically identify the manufacturer or distributor for prescription fills. For OTC purchases, store loyalty card data, credit card statements, and receipts may identify the retailer, from which the generic manufacturer can often be identified through the store's private-label supplier relationships. In practice, plaintiff's attorneys often name multiple defendants and establish that the claimant used ranitidine products from multiple manufacturers over their exposure period, supporting claims against the entire pool of defendants.